Dusan Perovic

NOTE: Dusan Perovic has departed Two Sigma Ventures. As of May 2026, he is Founding Partner at Deviation Capital, launched as a spinout of Two Sigma Ventures alongside Colin Beirne, Jonathan Golden, and Sidney Costabile. Two Sigma Ventures' website is no longer accessible; the promotion blog article source URL returned 404. Dusan was a Partner at TSV focused on techbio, life sciences, and healthcare AI. Engineering school gave him a deep fascination with biology, and his early career in biotech cemented his belief that the most enduring impact on humanity will come from companies applying engineering principles to improve human health. At Deviation, he continues to back founders fluent in both life sciences and engineering, with conviction that advances in data science, computing, and AI are unlocking previously unreachable problems in biology and medicine. He holds a degree from Princeton University. Notable TSV investments include Gameto (Series B lead; women's health/IVF; board director), Xaira Therapeutics ($1B raise; AI drug discovery), Terray Therapeutics ($120M Series B; AI-driven drug discovery), Arda Therapeutics (fibrosis; cell-depleting technology), and Freeform (AI metal 3D printing; $14M from NVIDIA and Boeing).